Organigram Global Financials - Benzinga

Organigram Global Inc

OGINASDAQ

Trade with Public

Trade with Public

$1.23

-0.0037-0.3%

Last update: Aug 28, 9:08 AM

Overview News Earnings ForecastFinancialsSentiment Compare Options Stock Report

Organigram Global Financials

Organigram Global (OGI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
OrganiGram Holdings Q3 Sales $76.413M Beat $67.660M Estimate

OrganiGram Holdings (NASDAQ:OGI) reported quarterly sales of $76.413 million which beat the analyst consensus estimate of $67.660 million by 12.94 percent. This is a 49.41 percent increase over sales of $51.142 million

Benzinga Newsdesk

PRO
Organigram Affirm Global FY2026 Revenue expected to be more than $255.197M vs $241.360M Est

Organigram Global (NASDAQ:OGI) affirm FY2026 Revenue expected to be more than $255.197M vs $241.360M Est

Benzinga Newsdesk

Organigram Says Vape Weakness Pressures Margins

Organigram reports weak Q2 fiscal 2026 results due to vape and pre-roll sales decline, but expects improvement with recent acquisition, operational changes.

Vandana Singh

PRO
Organigram Global FY2026 Revenue expected to be more than $350.000M vs $341.450M Est

Organigram Global (NASDAQ:OGI) FY2026 Revenue expected to be more than $350.000M vs $341.450M Est

Benzinga Newsdesk

PRO
OrganiGram Holdings Q2 EPS $(0.01), Inline, Sales $43.597M Miss $52.060M Estimate

OrganiGram Holdings (NASDAQ:OGI) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 100 percent decrease over earnings of $0.22 per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights